Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
November 20, 2024 16:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
October 25, 2024 07:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform
October 23, 2024 07:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel...
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
September 17, 2024 07:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel...
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
August 30, 2024 16:10 ET
|
Rakovina Therapeutics Inc
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a...
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
July 26, 2024 21:25 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
July 22, 2024 21:55 ET
|
Rakovina Therapeutics Inc
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a...
Rakovina Therapeutics Announces Second Upsizing of Private Placement
July 19, 2024 09:47 ET
|
Rakovina Therapeutics Inc
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a...
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
June 20, 2024 17:34 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update
May 30, 2024 17:52 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...